SCHEMBL17899863

SCHEMBL17899863

O=C(O)COc1ccc2ccccc2c1-c1c(O)ccc2ccccc12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.60
KDM4E B2RXH2 2/20 0.60
HPGD P15428 2/20 0.60
TDP1 Q9NUW8 1/20 0.60
PTPN7 P35236 1/20 0.50
CTSD P07339 1/20 0.49
ALOX5 P09917 1/20 0.49
GLA P06280 2/20 0.49
GAA P10253 1/20 0.49
HSD17B10 Q99714 1/20 0.49
PRNP P04156 1/20 0.46
RXFP1 Q9HBX9 1/20 0.46
ALOX15 P16050 1/20 0.46
MAPT P10636 3/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
POLB P06746 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
WDR5 P61964 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22169441 0.92 ALDH1A1 (0.70) ALDH1A1KDM4EHPGDTDP1PTPN7
SCHEMBL29506888 0.92 ALDH1A1 (0.70) ALDH1A1KDM4EHPGDTDP1PTPN7
SCHEMBL25917160 0.85 ALDH1A1 (0.60) ALDH1A1KDM4EHPGDTDP1PTPN7
SCHEMBL2521660 0.85 MAPT (0.65) ALDH1A1KDM4EHPGDTDP1PTPN7
SCHEMBL2526976 0.84 ALDH1A1 (0.59) ALDH1A1KDM4EHPGDTDP1PTPN7
SCHEMBL26632884 0.84 ALDH1A1 (0.59) ALDH1A1KDM4EHPGDTDP1PTPN7
SCHEMBL26736125 0.83 ALOX5 (0.55) ALDH1A1KDM4EALOX5GAAHSD17B10
SCHEMBL28434093 0.82 ALDH1A1 (0.65) ALDH1A1KDM4EHPGDTDP1PTPN7
SCHEMBL2523778 0.82 HPGD (0.56) ALDH1A1KDM4EHPGDTDP1PTPN7
SCHEMBL8257094 0.82 CNR1 (0.56) ALDH1A1KDM4EHPGDTDP1PTPN7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10173990-B2 URAT1 inhibitor NIPPON CHEMIPHAR CO., LTD. (JP) 2019-01-08 US disclosed
US-20170290795-A1 URAT1 INHIBITOR J-PHARMA CO., LTD. (JP) 2017-10-12 US disclosed
US-20170290795-A1 URAT1 INHIBITOR J-PHARMA CO., LTD. (JP) 2017-10-12 US disclosed
WO-2016108282-A1 URAT1 INHIBITOR 日本ケミファ株式会社 2016-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170290795-A1 URAT1 INHIBITOR SLC10A1, XDH, URB2 ALDH1A1 673/4885KDM4E 2799/4885HPGD 4581/4885
US-10173990-B2 URAT1 inhibitor SLC10A1, XDH, URB2 ALDH1A1 672/4885KDM4E 2791/4885HPGD 4601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.